4/A: Pfizer Executive Christoffel Boshoff Amends SEC Filing to Correctly Report Tax Withholding

Christoffel Boshoff, President of R&D at Pfizer, amends a previous SEC Form 4 filing to include a transaction involving the withholding of shares to cover tax obligations.

Summary

• Christoffel Boshoff, President of R&D at Pfizer, filed an amendment to a previous SEC Form 4 filing.
• The amendment corrects an omission in the original filing related to a transaction on February 24, 2025.
• The transaction involved the withholding of 403 common stock shares to satisfy tax obligations upon the vesting of restricted stock units.
• The shares were withheld at a price of $26.65 per share.
• Following the reported transaction, Boshoff directly owns 149,882 shares of Pfizer common stock.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a previous omission. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like Pfizer. It provides transparency into the transactions of company insiders.

Comparison to Industry Standards

• Executive stock ownership and transactions are common across publicly traded pharmaceutical companies.
• Companies like Johnson & Johnson (JNJ), Merck (MRK), and AbbVie (ABBV) also have executives who regularly report similar transactions via SEC filings.
• The level of stock ownership and the nature of transactions (e.g., vesting of restricted stock units, tax withholding) are generally consistent with industry practices for executive compensation.

Key Dates